5 completed, 2 terminated, 1 withdrawn. 8 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 5, Terminated 2, Withdrawn 1 |
| Phase 2 | 4 | Terminated 2, Completed 1, Withdrawn 1 |
Follow Brain Edema: new trials by email Literature Review of Brain Edema trials Research Report on Brain Edema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intravenous BCAA for HE in ACLF (BCAA-HE-ACLF) Branch Chain Amino Acid, Lactulose - Hepatic Encephalopathy, Acute-On-Chronic Liver Failure | Phase 1 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 114 | 2023-01-17 | 2025-06-08 |
| The Tolerability, Safety, and PK Characteristics of SIM1910-09 in Healthy Chinese Volunteers SIM1910-09, Placebo - Acute Ischemic Stroke, Cerebral Edema | Phase 1 | Completed | Jiangsu Simcere Pharmaceutical Co., Ltd. | 68 | 2021-12-06 | 2023-11-30 |
| Antisecretory Factor in Primary Glioblastoma 1 Salovum - Glioblastoma, Cerebral Edema | Phase 1 / Phase 2 | Completed | Peter Siesjö | 8 | 2019-09-01 | 2021-04-28 |
| Phase 1 Study to Assess AER-271 AER-271, Placebo - Stroke, Stroke, Acute | Phase 1 | Completed | Aeromics, Inc. | 80 | 2018-06-26 | 2020-07-09 |
| Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593) Glyburide, Placebo - Cerebral Edema, Brain Metastases | Phase 1 / Phase 2 | Terminated | University of Alabama at Birmingham | 1 | 2017-08-16 | 2022-09-21 |
| Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study Conivaptan - Cerebral Hemorrhage, Cerebral Edema | Phase 1 | Completed | Jesse Corry | 7 | 2017-03-22 | 2020-04-17 |
| Hypernatremia for the Prevention and Treatment of Cerebral Edema in Traumatic Brain Injury Induced, sustained hypernatremia using hypertonic saline, Standard of care (hypertonic saline and mannitol; serum sodium) - Traumatic Brain Injury, Subdural Hematoma | Phase 1 / Phase 2 | Withdrawn | Massachusetts General Hospital | 2012-07-01 | 2016-12-12 | |
| Tolerability Study of Xerecept® in Pediatric Patients XERECEPT - Brain Edema, Brain Tumor | Phase 1 / Phase 2 | Terminated | Celtic Pharma Development Services | 15 | 2010-06-01 | 2013-07-30 |
Brain Neoplasms (2) · Ischemic Stroke (2) · Stroke (2) · Acute-On-Chronic Liver Failure (1) · Brain Contusion (1) · Brain Diseases (1) · Brain Injuries (1) · Brain Injuries, Traumatic (1) · Central Nervous System Diseases (1) · Cerebral Hemorrhage (1) · Craniocerebral Trauma (1) · Edema (1) · Glioblastoma (1) · Head Injuries, Closed (1)
Brain Diseases (7) · Central Nervous System Diseases (7) · Nervous System Diseases (7) · Cardiovascular Diseases (4) · Cerebrovascular Disorders (4) · Vascular Diseases (4) · Neoplasms (3) · Pathological Conditions, Signs and Symptoms (3) · Central Nervous System Neoplasms (2) · Hemorrhage (2) · Metabolic Diseases (2) · Neoplasms by Site (2) · Nervous System Neoplasms (2) · Nutritional and Metabolic Diseases (2) · Pathologic Processes (2)
AER-271 (2) · Amino Acids (1) · Corticotropin-Releasing Hormone (1) · Glyburide (1) · Lactulose (1) · Mannitol (1) · Saline Solution, Hypertonic (1) · Standard of Care (1) · antisecretory factor (1) · conivaptan (1)
Aeromics, Inc. (1) · Celtic Pharma Development Services (1) · Jesse Corry (1) · Jiangsu Simcere Pharmaceutical Co., Ltd. (1) · Massachusetts General Hospital (1) · Peter Siesjö (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · University of Alabama at Birmingham (1)
United States (4) · China (1) · India (1) · Sweden (1)
Alex King, MD (1) · Brian P Walcott, MD (1) · Brian V Nahed, MD (1) · Jesse J Corry, MD (1) · Paul R McGuirk, PhD (1) · Sameer A Sheth, MD PhD (1) · Stewart Goldman, MD (1) · Yongjun Wang (1)